According to CoinMeta, Bid Pharma announced that its Indian subsidiary BLDIND recently received a "Notice of Reasons" from the customs in Bangalore, India. The customs intends to adjust the dutiable value of some historical imported goods of BLDIND, and seek the recovery of the difference in tariffs and interest, which may also involve fines. Currently, the matter is still in the stage of response and administrative adjudication, and no final decision has been made yet. The company and BLDIND have objections to some of the determinations and have hired professional institutions to assist in handling the situation, and will safeguard their legal rights and interests in accordance with the law. There is uncertainty regarding the outcome of this matter. If the relevant adjustments are adopted, it may have an adverse impact on the company's financial condition and operating results for that period. In 2025, BLDIND generated revenue of 115 million yuan, accounting for 8.65% of the company's consolidated revenue for the same period; from January to September 2026, BLDIND generated revenue of 90.1601 million yuan, accounting for 8.58%.